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Abstract. Numerous studies have pointed to low adherence to statin, which decreases as time period from acute 
cardiovascular event elapses. The aim was to analyze the cause of not taking statin by patients who were referred to 
rehabilitation after coronary event. Study population and methods. The research included the total of 573 patients, 
average age 60.3, while 305 (53.1%) of them were patients who experienced the first cardiovascular event. The stated 
research was conducted by means of a questionnaire and implied active participation of the researchers in terms of 
monitoring the possession and use of medication during rehabilitation. On arrival to rehabilitation, 98 (17.1%) patients 
did not have statin. They stated that they had never used statins before or that they stopped using them shortly after the 
event. This subgroup had significantly unfavorable values of lipid parameters (p<0.001), abdominal obesity (p<0.01), 
physical inactivity (p<0.01), more comorbidities (p<0.001), more prescribed medications on daily level (p<0.05), lower 
education degree level (p<0.01) and lower monthly income (p<0.001). Independent factors for not taking statin were: 
female gender, low monthly income and large number of comorbidities (R = 0.291, R2 = 0.85, adjusted R2 = 0.80, std. 
error of the estimate = 0.36151; p < 0.001). The patients themselves stated that the first reason for not taking statin was 
lack of financial funds (45.9%), while the second reason was normalization of laboratory results (21.4%). Three months 
after acute coronary event, 17.1% of patients in Serbia stopped taking statin. Lower adherence to statin closely 
correlates with female gender, low financial income and multiple comorbidities. 
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Introduction

 
The importance of statin in secondary prevention of cor-
onary disease was proved in 1994 after the publication of 
4S Study (Scandinavian Simvastatin Survival Study) 
which verified the reduction of mortality by 30% and 
coronary events by 34% [1]. After that, statin became a 
standard medication in secondary prevention therapy and 
was to be found in all manuals which refereed to second-
ary prevention of new cardiovascular events [2]. Obser-
vational study which was conducted in Europe showed 
that the percentage of prescribed medication at discharge 
after acute coronary event was very low, as well as that 
target values of lipid parameters were not in accordance 
with the recommendations, regardless of the fact that 
adequate medications were used [3]. The authors of an-
other study have emphasized that statins were prescribed 
in 90% of hospital discharges and that they are now pre-
sent  in therapy of 84% of patients after 12 month follow-
up [4]. When it comes to clinical practice, statins are not 
very welcomed by patient or even by some doctors. There 
are numerous prejudices which discriminate statins as 
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"dangerous medications which destroy liver and mus-
cles". Additionally, statin-based therapy is not always 
optimal and does not help in achieving targeted values of 
lipid parameters [5,6]. 
Having in mind the above stated, the objective of the 
study was to analyze the cause of not taking statin by 
patients who were referred to rehabilitation after coro-
nary event, as well as to propose measures for increas-
ing adherence to statin therapy. 
Study Population and Methods 
The research included all patients with coronary events 
(acute myocardial infarction with or without stent im-
plementation, coronary revascularization) who were 
referred to cardiovascular rehabilitation at the Institute 
for Treatment and Rehabilitation “Niška Banja”. The 
patients came from all Serbian regions, except Belgrade. 
The stated research started in January 2013 at one of 
Cardiovascular Rehabilitation departments. By the end 
of 2016, the research included 573 patients who consec-
utively came to rehabilitation, 305 (53.1%) of whom 
had one cardiovascular event, while others came after a 
recurrent cardiovascular event.   
Research was carried out by means of a questionnaire 
and active participation of the researchers. A patient 
could answer the question by circling one of the offered 
answers. If the formulation of the answer was not satis-
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factory, the patient could give her/his own answer to the 
questions which referred to the reasons for not taking 
statins. Additionally, patients were free to write the pri-
mary reason for not taking statin. During the first exami-
nation, the researchers registered all medications that 
patients brought with them and monitored the use of 
medication during rehabilitation.   
On examination, the weight, height and waist cir-
cumference of patients were measured. All patients 
were subjected to standard laboratory analysis with the 
aim of assessing risk factors - glycemia and lipid status 
(total cholesterol, HDL cholesterol, LDL cholesterol 
and triglycerides). Arterial blood pressure was measured 
on daily basis throughout three-week rehabilitation and 
the average values were calculated.   
Statistical data analysis was carried out by means of 
SPSS 17.0 software. The results were shown either as 
arithmetic mean and standard deviation (X±SD) or as 
absolute value and percentage. Student's t-test was used 
for testing parameter values. The value of p < 0.05 was 
accepted as statistically significant. Non-parametric val-
ues were tested by χ2-test. Spearman's rank correlation 
coefficient was used for assessing statistical significance 
of correlation. Multivariate regression analysis was car-
ried out with the aim of defining independent predictors 
for not taking statin.  
Results 
In terms of gender structure, there were 68.6% of male 
and 31.4% of female patients (Table 1). Majority of 
patients completed four-year secondary education – 284 
(49.6%), while 171 (29.8%) patients completed ele-
mentary education. The total of 86 (15%) patients had 
higher education degree and 32 (5.6%) patients had no 
formal education whatsoever. On average, the patients 
who did not use statins had lower education degree level 
(p<0.01; Table 1). The subgroup of patients who did not 
take statin had higher values of total cholesterol, LDL 
cholesterol (p<0.001) and triglycerides (p<0.01). More-
over, general obesity and abdominal obesity (p<0.01), 
physical inactivity (p<0.01) and presence of positive 
heredity for cardiovascular disease (p<0.001) were quite 
present among the members of this subgroup. Addition-
ally, patients from this subgroup had more prescribed 
medications a day as compared to the subgroup which 
took statins (8.2±2.8 vs. 7.5±2.8; p<0.05). 
Multivariate regression analysis included the following 
parameters: age, gender, education, income, number of 
comorbidities, recurrent cardiovascular events, time which 
elapsed from cardiovascular event, total number of 
medications taken per day. This statistical method defined 
female gender (coefficient β = 0.152), monthly income 
(coefficient β = -0.162) and comorbidities (coefficient β = 
0.129) as independent factors for not taking statin in this 
model (for model: R = 0.291, R2 = 0.85, adjusted R2 0.80, 
std. error of the estimate 0.36151; p < 0.001).  
Table 2 shows the distribution of previously formu-
lated answers in terms of the reasons for not taking statin.  
In terms of percentage of patients who used some 
kind of reminder for taking medication (medication 
dosette, notes, telephone, another person, etc.), the fig-
ures were not much different in group which did not 
take medications as compared to the group which took 
medications (30.6% vs. 34.9%). 
When asked to state the main reason for not taking 
statin, majority of patients – 45 wrote that the main 
problem was lack of financial funds (Figure 1), 21 pa-
tients wrote that their laboratory results of lipid status 
were normal, 11 patients had new health problems, 10 
patients were not prescribed statin until the period of 
rehabilitation, physician discontinued therapy in 7 pa-
tients, while 4 patients wrote down that the main reason 
for not taking statin was their forgetfulness and negli-
Table 1 Clinical features of all patients and differences in parameters in patients who take statin as compared to 
patients who do not take statin.  
Parameters  All patients Patients  
who take statin 
Patients  
who do not take statin 
Gender m/f   393 /180  346 / 129  47 / 51
***
 
Age   60.3 ± 9.9  60.3  ±  9.0  60.5  ± 10.1 
Education (level)*  2.8 ± 0.9  2.9 ±  0.9  2.6  ± 0.6
**
 
Smoking (n/%)  288  (50.2%)  252  (46.9%)  36  (36.7%) 
Waist (cm)  99.0 ± 11.8  98.4  ± 12.2  101.8  ±  9.4
*
 
Abdominal obesity (n/%)  292  (50.9%)  228 (48.0%)  64 (65.3%)
**
 
Body mass index (g/m
2
)  27.5  ±  4.2  27.3  ±  4.2  28.6  ± 4.4
**
 
Total cholesterol (mmol/L)  4.4  ±  1.1  4.4  ± 1.0  4.9  ± 1.1
***
 
HDL cholesterol (mmol/L)  1.1  ±  0.3  1.1  ±  0.4  1.0  ±  0.2 
LDL cholesterol (mmol/L)  2.5  ±  0.9  2.5  ±  0.9  2.9  ± 0.9
***
 
Triglyceride (mmol/L)  1.8  ±  1.0  1.9  ±  0.9  2.1  ± 1.5
**
 
Glycemia (mmol/L)  6.1  ±  2.1  6.1   ± 2.1  6.0  ±  1.7 
Systolic pressure (mmHg)  124.2  ± 15.8  123.8  ± 14.4  126.4  ± 21.3 
Diastolic pressure (mmHg)  77.7  ±  6.2  77.6  ±  6.1  78.2  ±  6.7 
Heredity (n/%)  354  (61.8%)  273  (57.5%)  81  (82.6%)
***
 
Physical inactivity (n/%)  148 (25.8%)  110  (23.1%)  38  (38.8%)
**
 
m – male; f – female; HDL – high-density lipoprotein; LDL – low-density lipoprotein 
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gence. In terms of health issues that the patients con-
nected with the use of statin, 32 (6.7%) patients reported 
minor health issues (as compared to subgroup that did 
not take statins p<0.05), but they still took the pre-
scribed therapy.  
Discussion 
Nowadays, there is a tendency for standardizing the 
definition of adherence in medical therapy with the aim 
of using and comparing data in electronic database, 
which would make an exceptional base for conducting 
future meta-analysis [7]. This study could not determine 
Proportion of Days Covered (PDC) and/or Medication 
Possession Ratio (MPR), having in mind that the pa-
tients have been referred to rehabilitation from various 
regions in Serbia. However, we could detect the patients 
who do not take statins by simple physical inspection of 
the medications which they have brought at the first 
examination. We have found that 17.1% of the patients 
stopped taking statins after 3.2 months from the last 
acute cardiovascular event. The patients have filled out 
a questionnaire which contained the reasons for not 
taking statins and could write down the main reason for 
not taking the medication. 
It is well known that high blood cholesterol levels 
are associated with an increased risk of CVD events and 
deaths, and the use of statins is associated with a sig-
nificant reduction in that risk [8].  In the modelling-
based study of Yang et al., under the 2013 Guidelines 
for primary prevention of atherosclerotic cardiovascular 
disease using statin therapy, up to 12.6% of total annual 
atherosclerotic cardiovascular disease deaths could be 
prevented among adults aged 40–75 who are eligible for 
statin treatment [9,10]. However, these prevented deaths 
could be accompanied by additional cases of diabetes or 
myopathy. The study by Xie et al. pointed out the im-
portance of adherence to statin therapy in prevention of 
major adverse cardiac events (MACE) and thus clini-
cians should aim to achieve higher dosage, if tolerable 
[11]. Therefore, nonadherence represented an important 
therapy problem in clinical medicine, especially in 
terms of implementation of guideline for good clinical 
practice. The study by Kumbhani et al. proved low ad-
Table 2 Distribution of potential reasons for not taking statin 
Potential reason for not taking the medication Number of patients (n / %) 
Physician did not recommend the medication upon hospital discharge  28 (28.6) 
Medication was not prescribed by primary health protection physician 41 (41.8) 
Low monthly income in the family  71 (72.4) 
I forgot to take the medication (always or sometimes) 39 (40.1) 
Lack of information regarding medication benefits  32 (32.6) 
Medication was discontinued when lipid status was within normal limits  36 (36.7) 
I am cured (by-pass or stent), I do not need medication 12 (12.2) 
I am afraid that “medication does not go well with other medications”  82 (83.7) 
I am afraid that I may damage other organs  38 (38.8) 
Medication caused new health issues  14 (14.3) 
I was worried (frightened) when I read medication instruction  0   (0.0) 
I cannot purchase the medication (no specific reason) 58 (59.1) 
I decided to stop taking the medication on my own  89 (90.8) 
 
Fig. 1 Distribution of main reasons for not taking statin, according to patient’s statements 
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herence to medications for secondary prevention 
(48.2%) after one-year follow-up of arteriosclerosis 
(37154 patients), as well as high frequency of unwanted 
cardiovascular events and mortality in nonadherent 
group [12].  Bansilas et al. demonstrated that frequency 
of large unwanted cardiovascular events was signifi-
cantly lower in cases of total adherence (statins and 
ACE inhibitors), i.e. ≥80% of days covered by therapy, 
as compared to partial adherence and nonadherence in 
patients after myocardial infarction [13]. They found 
that adherence had to be minimum 40% for longer pe-
riod of time so that the difference in disease outcome 
would be noticeable. Furthermore, after examining a 
group of patients with diabetes, Ruokoniemi et al. stated 
that reduced MACE incidence was observed in patients 
without any documented cardiovascular disease at statin 
initiation odds ratio (OR) 0.87 (95% CI 0.78–0.96) 
overall and OR 0.80 (95% CI 0.66–0.97) for those who 
were subjected to 5-year or longer follow-up [14]. The 
authors concluded that good adherence to statins (the 
proportion of days covered ≥ 80%) predicted reduced 
incidence of MACEs, irrespective of the presence of 
coronary heart diseases at statin initiation. 
In order to increase the level of adherence, which is 
based on forgetfulness and/or negligence, the literature 
has offered various types of reminders for taking medi-
cations. For instance, daily alarms combined with indi-
vidual or partner feedback improved statin medication 
adherence [15]. The total of 40% of the members of our 
group stated that they occasionally forgot to take the 
medication. However, this was not a crucial reason for 
not taking statin, as forgetfulness was equally present in 
both subgroups.   
Based on research results, Latry et al. concluded that 
adherence to statins was poor, but better for those pa-
tients with higher number of associated cardiovascular 
risk factors [16]. The results confirmed that long-term 
drug treatments were a difficult challenge, particularly 
for patients who could not see the benefit or felt that 
they were at risk. Patients at high risk for cardiovascular 
events were suboptimally dosed with statins, had high 
rates of discontinuation and low rates of adherence. De-
spite the use of statin therapy, atherosclerotic cardiovas-
cular disease-related inpatient visit rates were high, par-
ticularly among those patients at highest risk because of 
a recent acute coronary syndrome hospitalization [17]. 
In terms of our study, an independent factor for not 
taking statins was large number of comorbidities. Addi-
tionally, larger number of prescribed medications that 
patients had to take significantly reduced adherence to 
statins. Larger number of comorbidities and prescribed 
medications required significant financial funds in home 
budget, which reduced adherence to statins. Our study 
has proved that one of independent factors for not taking 
statins is low family income, which has a logical correla-
tion with two previously stated reasons. We have not no-
ticed differences in answer distribution in tested sub-
groups when it comes to statin significance, prolongation 
of life by the use of statins, normalization of lipid param-
eter level, organ damage due to statins or fear from medi-
cation interaction. Therefore, our research has demon-
strated that reasons for not taking statins are not subjec-
tive, but are objective, i.e. they correlate with education 
degree, financial conditions, the fact that physician has 
not prescribed medication or discontinued medication. 
This points to the significance of the problem of adher-
ence to statin in therapy. Unfortunately, this problem 
goes way beyond medical profession. 
Conclusion 
On average, 17.1% of patients in Serbia have stopped 
taking statins 3.2 months after acute coronary event. 
Low adherence to statins was closely correlated with 
female gender, low home budget and larger number of 
comorbidities. 
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